Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Gastric Tumors: an overview

Written2008-11Paul Lochhead, Emad El-Omar
Gastrointestinal Research Group, Division of Applied Medicine, School of Medicine, Dentistry, Aberdeen University, Aberdeen AB25 2ZD, Scotland, UK

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C160-C166,C168-C169 STOMACH
Atlas_Id 5410
Phylum Digestive organs: Stomach::Gastric tumor
Note The vast majority of both benign and malignant tumours of the stomach are of epithelial origin, with mesenchymal and neuroendocrine tumours being much less common. Gastric adenocarcinoma comprises in excess of 95% of malignant neoplasms of the stomach, and is thus the focus of this overview. Primary gastric lymphoma is the second commonest malignancy affecting the stomach with gastrointestinal stromal tumours (GISTs) and rare tumours, such as carcinoids, accounting for the remainder of cases.

Classification

    Benign Tumours
    Neoplastic
  • Epithelial adenomas
  • Fundic gland polyps
  • GISTs
  • Lipomas
  • Leiomyomas
  • Neural tumours (e.g. Schwannomas)

Malignant Tumours

  • Adenocarcinoma
  • Primary gastric lymphoma
  • GISTs
  • Metastatic deposits
  • Carcinoids
  • Rare tumours
    • e.g. Sarcomas, neuroendocrine carcinoma, primary squamous cell carcinoma and adenoacanthomas

Clinics and Pathology

Disease Benign Gastric Polyps
Note Benign gastric polyps are found incidentally in 2-3% of upper gastrointestinal endoscopies. Their incidence increases with patient age. Small polyps are almost always asymptomatic. Larger polyps may bleed due to erosions or ulceration. Very large distal polyps may produce obstructive symptoms.
Small hyperplastic and fundic gland polyps are relatively common. They are generally regarded as being of no significance although multiple fundic gland polyps with evidence of dysplasia can occur in familial adenomatous polyposis (FAP). Fundic gland polyps and, to a lesser extent, hyperplastic polyps, occur with increased frequency in patients on long-term proton pump inhibitor therapy.
Inflammatory fibroid polyps (IFPs) are uncommon solitary lesions that arise in the distal stomach. They usually originate submucosally however the overlying mucosa commonly develops erosions or ulceration. IFPs are felt to be reactive in nature and are composed of a mixture of proliferating fibroblasts, blood vessels and inflammatory cells. Eosinophils are often present. Helicobacter pylori has been implicated in the etiology of IFPs as have chemical and mechanical irritants.
Adenomatous polyps in the stomach usually arise against a background of chronic atrophic gastritis with intestinal metaplasia although they too can occur in FAP. Gastric adenomata are composed of dysplastic epithelium with tubular and/or villous architecture. Polyp size and the grade of dysplasia are felt to be predictors of progression to carcinoma. Because gastric adenomata, like those in the colon, represent a pre-malignant condition, excision (usually possible endoscopically) is the treatment of choice.

Disease Gastric adenocarcinoma
Etiology
  • Helicobacter pylori
    H. pylori is the single most important etiological agent in the pathogenesis of gastric cancer. Numerous epidemiological studies have demonstrated an association between serological evidence of H. pylori infection and gastric cancer risk. The conclusion of several meta-analyses of these data is that chronic H. pylori infection confers around a two-fold increase in the risk of developing gastric cancer. H. pylori strains expressing the cytotoxin-associated gene A antigen (CagA) are associated with a further two-fold increase in gastric cancer risk. The association with H. pylori appears strongest for non-cardia gastric cancer, but applies to both intestinal and diffuse histological subtypes.
    With respect to cancer of the gastric cardia, recent data suggest that there are two distinct etiological subtypes: one arising in the context of severe atrophic gastritis and akin to non-cardia cancer, and a second arising in non-atrophic mucosa, associated with gastro-oesophageal reflux disease and resembling oesophageal adenocarcinoma.

  • Host Genetics
    Individual differences in the inflammatory response to H. pylori infection, as determined by host genetic polymorphisms, may predispose to the development of a gastric cancer phenotype. Pro-inflammatory polymorphisms have been described in the interleukin-1 gene cluster, and tumour necrosis factor-alpha, interleukin-10, interleukin-8, and interferon-gamma genes. Having an increasing number of such pro-inflammatory genetic polymorphisms confers an increased gastric cancer risk for an H. pylori-infected individual.

  • Diet and Smoking
    It has been postulated that diets rich in fruit and vegetables are associated with a reduced risk of gastric cancer. To date, data from large prospective studies do not bear this out. Similarly, there are conflicting data regarding the increased risk associated with dietary salt and nitroso compound intake.
    There is a dose-dependent relationship between smoking and gastric cancer. It is estimated that over 17% of gastric cancers in Europe are directly attributable to cigarette smoking.
  • Epidemiology Gastric cancer is the second most common cause of cancer-related death globally. Although the incidence of gastric cancer has fallen significantly in most countries over the past 70 years, the global incidence is predicted to rise as a result of population growth. There are marked geographical variations in the incidence of gastric cancer. The highest incidence is found in Eastern Asia, Eastern Europe and South America. In all populations studied thus far, there is a male preponderance in gastric cancer incidence with an average male to female ratio of 2:1.
    Clinics Early gastric cancer is most likely asymptomatic in most patients, or may produce non-specific dyspeptic symptoms. Alarm symptoms such as anorexia, weight loss, dysphagia or gastrointestinal haemorrhage usually betray advanced disease.
    Pathology Historically, gastric cancers were classified according to the Laurén classification as being of either intestinal or diffuse histological type. The pathogenesis of intestinal type gastric cancer has been defined as following a pathway from atrophic gastritis, through intestinal metaplasia and dysplasia, to frank malignancy. No such pathogenic sequence of progression exists for diffuse type gastric cancer. More recently, gastric cancers have been classified anatomically as either cardia or non-cardia in origin.
     
    Photomicrograph of a poorly differential intestinal type adenocarcinoma of the stomach. (Courtesy of Prof G Murray, Dept. of Pathology, University of Aberdeen)
    Treatment Resection with curative intent is the only treatment that will result in long-term survival from gastric adenocarcinoma. Palliative and neo-adjuvant chemotherapy improve survival in selected patients.
    Prognosis In Western countries, 90% of gastric cancers are inoperable at presentation and thus 5-year survival rates at are low. In Japan, where population-based screening takes place, 5-year survival exceeds 50%.

    Disease Primary gastric lymphoma
    Note The vast majority of primary lymphomas arising in the stomach are of non-Hodgkin's B-cell type. Recent series have demonstrated that low-grade marginal zone lymphomas of mucosa-associated lymphoid tissue (or MALT lymphomas) account for over 50% of cases of primary gastric lymphoma. Historically the predominant histological type was diffuse large B-cell lymphoma (DLBCL).
    Etiology The gastric mucosa is normally devoid of lymphoid tissue. H. pylori is implicated as an etiological agent in over 92% of cases of gastric MALT lymphoma. Chronic H. pylori infection results in a lymphoid follicular gastritis and so to the acquisition of gastric MALT. MALT lymphomagenesis is thought to be dependent on clonal expansion driven by H. pylori antigenic stimulation. The mechanisms involved in the transformation of low-grade gastric MALT lymphoma to high grade DLBCL are not well understood.
    Clinics Patients with primary gastric lymphoma may present with non-specific dyspeptic symptoms, early satiety, or evidence of gastrointestinal haemorrhage due to ulcerating disease. Systemic symptoms may be present in advanced stage disease.
    Pathology MALT lymphomas display cellular heterogeneity. Lymphoid follicles may be present with tumour cells located in the marginal zone. Lymphoepithelial lesions are typical in gastric MALT lymphoma. Staging, using a modified Ann Arbor system, can be achieved using endoscopic ultrasonography.
    Treatment Eradication of H. pylori using standard antibiotic regimens results in complete response in around 75% of patients with limited stage MALT lymphoma. Patients who fail to respond to antibiotic therapy, are H. pylori negative, or have nodal disease may be treated in a similar manner to other lymphomas with the use of systemic chemotherapy (e.g. CHOP), immunotherapy (e.g. Rituximab) and/or radiotherapy for localized disease. There is no evidence that surgery is superior to medical therapy alone although surgical intervention may be appropriate in specific scenarios such as gastric outlet obstruction.
    Prognosis The response of low grade MALT lymphoma to H. pylori eradication is predicted by stage. Complete response is achieved in all patients where disease is limited to the gastric mucosa or submucosa. Complete response rates fall where disease extends to the muscularis or serosa, and no patients with nodal disease achieve complete response with H. pylori eradication alone.
    The presence of the cytogenetic aberration t(11;18)(q21;q21) predicts lack of response to H. pylori eradication and is found frequently in H. pylori negative MALT lymphomas. Strong nuclear expression of BCL10, associated with t(1;14)(p22;q32), is also associated with lack of response to antibiotic therapy.

    Disease Gastrointestinal Stromal Tumours
    Note Gastrintestinal stromal tumours (GISTs) are the commonest mesenchymal tumours of the GI tract. They are defined by the expression of CD117 ( c-KIT ), a receptor tyrosine kinase. Gain-of-function mutations in KIT or the platelet derived growth factor alpha gene ( PDGFA ) are critical to GIST tumourigenesis. Around 60% of GISTs arise in the stomach and approximately 25% of gastric GISTs display clinically malignant behaviour. GISTs, however, account for only 1-3% of malignant tumours of the stomach.
    Most GISTs are sporadic although a small percentage occur in the context of neurofibromatosis type 1 and the very rare Carney triad (in association with functioning extra-adrenal paragangliomas and pulmonary chondromas).
    Clinics Small GISTs may be asymptomatic or found incidentally at upper GI endoscopy. Acute or chronic gastrointestinal haemorrhage, due to ulceration of the gastric mucosa superficial to a GIST, is the commonest clinical presentation. Large GISTs may produce symptoms of gastric outlet obstruction or present with pain/dyspepsia, early satiety and nausea.
    Pathology Gastric GISTs are highly cellular and tend to be of either spindle cell or epithelioid subtypes. The distinction between benign and malignant GISTs is not clear-cut, rather they display a spectrum of biological behaviour. Mitotic index, size and the use of immunohistochemical proliferation markers may give an indication of the malignant potential of a GIST.
    Treatment Surgical resection is the treatment of choice for GISTs. There are favourable trial data supporting the use of the tyrosine kinase inhibitor, Imatinib, in patients with metastatic or unresectable GISTs.

    Disease Gastric Carcinoid
    Note Gastric carcinoid tumours are rare, comprising only 0.5% of gastric tumours. They arise in the oxyntic mucosa of the gastric corpus and fundus and are comprised of non-functioning enterochromaffin-like cells. Gastric carcinoid tumours may be sporadic or can occur in the context of autoimmune atrophic gastritis, Zollinger-Ellison syndrome and in the MEN-1 syndrome. Carcinoid tumours over 2cm in size are associated with an increased risk of lymphovascular invasion and metastasis, and resection is recommended.

    Genetics

    Note Around 10-15% of gastric cancers are familial. Hereditary diffuse gastric cancer (HDGC) is a highly penetrant autosomal dominant condition with an average age at diagnosis of 38 years. Around one third of families have inactivating mutations in the E-cadherin gene. Increased gastric cancer risk is observed in a number of dominantly-inherited cancer predisposition syndromes including hereditary nonpolyposis colon cancer (HNPCC), familial adenomatous polyposis (FAP), Peutz-Jegher's syndrome and in BRCA2 mutation carriers.

    Cytogenetics

    Cytogenetics
    Morphological
    Numerous abnormalities of chromosome structure and number have been reported in gastric cancer series although no specific aberration has yet been identified.
    Those chromosomes most commonly involved in simple numerical aberrations include X, Y, 1, 7, 8, 9, 17 and 20. Polysomy for chromosome 17 has been reported to be associated with lymphovascular invasion and nodal metastases.
    Conventional cytogenetic analysis of 15 gastric cancers using G-banding revealed structural aberrations most commonly involving chromosomes 1, 11, 14, 7, 17, 6, 8 and 13. The aberration add(11)(p15) was found in five of the cancers analysed.
    Multicolour spectral karyotyping has been employed to identify recurrent chromosomal rearrangements in gastric cancer cell lines. Chromosome 8 was most commonly involved in rearrangements. Recurrent translocations, frequently involving known oncogene and tumour-suppressor gene loci, were identified with breakpoints most frequently occurring at bands 8q24 and 11q13.
    Cytogenetics Molecular Comparative genomic hybridization has been used to screen for abnormalities of copy number in gastric cancers. In a study of 62 gastric adenocarcinomas, and 6 cell lines, 84% of tumours and all of the cell lines showed changes in DNA copy number. Specific patterns of allelic gains and losses appeared to correlate with different histopathological and disease-related features, such as metastases.
    Loss of heterozygosity (LOH) studies in gastric adenocarcinomas have shown high LOH at chromosome arms 1p, 3p, 4p, 5q, 7p, 8p, 9p, 12q, 13q, 17p, 18q and 22q. The intratumoural distribution of LOH between early and advanced gastric cancer has been compared, and suggests that multiple losses occur as an early event in tumorigenesis with a few sporadic losses occurring later in disease progression.

    Genes involved and Proteins

    Gene NameCDH1 (cadherin 1, type 1, E-cadherin (epithelial))
    Location 16q22.1
    Protein CDH1 encodes E-cadherin, a member of the cadherin superfamily of calcium-dependent cell adhesion molecules. Downregulation of E-cadherin is observed in a number of epithelial-derived human cancers and promotes invasion through loss of epithelial cell-cell adhesion.
    Germinal mutation Approximately 30-40% of HDGC kindred harbour germ line mutations in CDH1.
    Somatic mutation Somatic mutations are found in more than 50% of diffuse type gastric cancers but are not found in the intestinal histological type. There is a significant rate of LOH for CDH1 in sporadic gastric cancers (SGCs) of both histological types. Downregulation via promotor hypermethylation, along with mechanisms acting at transcriptional and post-transcriptional level, may act as the second hit in both inherited and sporadic diffuse cancers.

    Gene NameMYC v-myc myelocytomatosis viral oncogene homolog (avian)
    Location 8q24.21
    Protein The C-MYC proto-oncogene encodes a transcription factor involved in activation of a number of genes involved in cell proliferation.
    Somatic mutation C-MYC amplification/overexpression has been described in around 16% of SGCs. Allelic gain through chromosome 8 polysomy has been suggested as an important mechanism of C-MYC amplification in SGCs. C-MYC locus amplification is associated with increased aggressiveness and metastasis in intestinal-type tumours.

    Gene NameERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian))
    Location 17q12
    Protein C-ERBB2 (HER2) encodes p185, a tyrosine kinase cell surface receptor structurally similar to human epidermal growth factor receptor ( EGFR ). The protein conformation of p185 permanently resembles the ligand-bound state of EGFR. p185 is a potential target for trastuzumab (Herceptin) therapy.
    Somatic mutation C-ERBB2 is amplified/overexpressed in 8-30% of gastric cancers. C-ERBB2 expression is more common in intestinal type tumours and is a marker of invasion and metastasis. Somatic mutations within the kinase domain have been reported in gastric cancers as well as other solid tumours.

    Gene NameMET met proto-oncogene (hepatocyte growth factor receptor)
    Location 7q31.2
    Protein The MET proto-oncogene encodes a transmembrane high affinity receptor for hepatocyte growth hormone.
    Germinal mutation A small number of case reports exist of germ line mutations in MET predisposing to gastric cancer.
    Somatic mutation Overexpression of C-MET has been reported in both histological subtypes of gastric cancer and is associated with poor prognostic features. The H. pylori CagA protein appears to interact with the MET protein leading to activation.

    Gene NameAPC (adenomatous polyposis coli)
    Location 5q22.2
    Protein The APC tumour suppressor protein is a key component of the WNT / Beta-catenin signalling pathway.
    Germinal mutation Gastric fundic gland polyps are observed as an extracolonic feature of FAP. Occasional malignant transformation has been reported.
    Somatic mutation Whilst somatic APC mutations are common in gastric cancers, their significance with regards to tumorigenesis remains unclear. It has been postulated that APC mutations play a role in adenoma formation and dysplasia, rather than the promotion of malignant progression.

    Gene NameTP53 (Tumour protein p53 (Li-Fraumeni syndrome))
    Location 17p13.1
    Protein The transcription factor p53 plays a critical role in cell cycle arrest, senescence, DNA repair and apoptosis.
    Germinal mutation Although not one of the classical Li-Fraumeni-associated neoplasms, early onset gastric cancers occur uncommonly in Li-Fraumeni Syndrome (LFS) kindred. Case reports exist of familial gastric cancer in Japanese and Korean families with germ line p53 mutations. It has been suggested that LFS may give rise familial clustering of gastric cancer in regions with high gastric cancer incidence.
    Somatic mutation Loss of functional p53 has been reported in virtually all human cancers including gastric cancers. Data on the significance of p53 mutations in SGC development, progression, and prognosis are conflicting.

    Gene NameFGFR2 (fibroblast growth factor receptor 2)
    Location 10q26.13
    Protein K-SAM encodes the fibroblast growth factor receptor 2.
    Somatic mutation The oncogene K-SAM is amplified/overexpressed in approximately 50% of diffuse type gastric cancers but not in the intestinal histological type.

    Gene NamePTGS2 (prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase))
    Location 1q31.1
    Note COX2 is upregulated in 49-83% of gastric cancers. COX2 expression is particularly high in early gastric cancers suggesting that it may play an important role in early events in tumorigenesis. There is conflicting evidence on the association between H. pylori and the induction of COX2 in gastric cancer.
    Protein Cyclo-oxygenase 2 is an inducible enzyme responsible for regulating prostaglandin biosynthesis. COX2 activity is normally undetectable in gastric mucosa.

    Gene NameRUNX3 (runt related transcription factor 3)
    Location 1p36.11
    Protein The runt-related transcription factor 3 acts as a tumour suppressor protein.
    Somatic mutation Silencing of RUNX3 has been reported in up to 60% of gastric cancers and appears to be effected through hypermethylation of CpG islands within the exon 1 region. Hemizygous deletion of RUNX3 is observed in around 30% of gastric cancers, whilst mutations and small deletions seem to be rare.

    Gene NameSPEN (spen family transcriptional repressor)
    Location 1p36.21
    Protein The phosphate and tensin homolog acts as a tumour suppressor. The protein is involved in regulation of cell cycle progression in he G1 phase. Inactivation of PTEN is observed in multiple advanced cancers and cancer cell lines.
    Germinal mutation Gastric hyperplastic polyps are a recognised feature of Cowden's syndrome although these are generally considered non-neoplastic.
    Somatic mutation LOH for PTEN has been reported as 20% for early gastric cancers compared to 30% for advanced cancers. The mutation rate in advanced gastric cancers is around 10%.

    Gene NameDNA repair
    Note 3p21.3 ( MLH1 ), 2p22-p21 ( MSH2 ), 2p16 ( MSH6 ), 5q11-q12 ( MSH3 ), 14q24.3 ( MLH3 ), 3q21-q22 ( MBD4 )
    Protein DNA mismatch repair (MMR) enzymes.
    Germinal mutation Gastric adenocarcinoma is a recognised part of the hereditary nonpolyposis colon cancer (HNPCC) spectrum of tumours. Dominantly inherited germ line mutations in MLH1 and MSH2 account for 90% of cases of HNPCC. HNPCC confers a 5% lifetime risk of gastric cancer.
    Somatic mutation Micosatellite instability (MSI) is the hallmark of defects in the MMR system. Around 15% of SGCs show MSI, most frequently due to hypermethylation of the MLH1 promoter. Recent data suggest that mutations in known MMR genes in SGCs are uncommon and likely arise as a result of the mutator phenotype, rather than cause it.

    Bibliography

    C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
    Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M.
    Anticancer Res. 2006 Jul-Aug;26(4B):2909-14.
    PMID 16886612
     
    Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma.
    Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpcao PP, Faria MH, Rabenhorst SH, Ferreira MV, de Arruda Cardoso Smith M, Burbano RR.
    World J Gastroenterol. 2006 Oct 14;12(38):6207-11.
    PMID 17036397
     
    Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer.
    Carneiro F, Oliveira C, Suriano G, Seruca R.
    J Clin Pathol. 2008 Jan;61(1):25-30. Epub 2007 May 18.
    PMID 17513507
     
    Evidence for two modes of allelic loss: multifocal analysis on both early and advanced gastric carcinomas.
    Chung YJ, Choi JR, Park SW, Kim KM, Rhyu MG.
    Virchows Arch. 2001 Jan;438(1):31-8.
    PMID 11213833
     
    Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response.
    Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M.
    J Cell Biol. 2003 Apr 28;161(2):249-55.
    PMID 12719469
     
    Epidemiology of gastric cancer.
    Crew KD, Neugut AI.
    World J Gastroenterol. 2006 Jan 21;12(3):354-62.
    PMID 16489633
     
    Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer.
    Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, Rakhshani N, Didevar R, Sotoudeh M, Zolfeghari AA, McColl KE.
    Gut. 2008 Mar;57(3):298-305. Epub 2007 Oct 26.
    PMID 17965056
     
    Role of host genes in sporadic gastric cancer.
    El-Omar EM.
    Best Pract Res Clin Gastroenterol. 2006;20(4):675-86.
    PMID 16997152
     
    Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome.
    Garrean S, Hering J, Saied A, Jani J, Espat NJ.
    Am Surg. 2008 Jan;74(1):79-83.
    PMID 18274437
     
    Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST).
    Gonzalez CA, Pera G, Agudo A, Bueno-de-Mesquita HB, Ceroti M, Boeing H, Schulz M, Del Giudice G, Plebani M, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Siman H, Hallmans G, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Bingham S, Day NE, Linseisen J, Nagel G, Overvad K, Jensen MK, Olsen A, Tjonneland A, Buchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Roukos D, Trichopoulou A, Psaltopoulou T, Lund E, Casagrande C, Slimani N, Jenab M, Riboli E.
    Int J Cancer. 2006 May 15;118(10):2559-66.
    PMID 16380980
     
    Familial gastric cancers with Li-Fraumeni Syndrome: a case repast.
    Kim IJ, Kang HC, Shin Y, Yoo BC, Yang HK, Park JG.
    World J Gastroenterol. 2005 Jul 14;11(26):4124-6.
    PMID 15996045
     
    Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma.
    Lee JH, Abraham SC, Kim HS, Nam JH, Choi C, Lee MC, Park CS, Juhng SW, Rashid A, Hamilton SR, Wu TT.
    Am J Pathol. 2002 Aug;161(2):611-8.
    PMID 12163385
     
    Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
    Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.
    Clin Cancer Res. 2006 Jan 1;12(1):57-61.
    PMID 16397024
     
    Causal relationship between the loss of RUNX3 expression and gastric cancer.
    Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y.
    Cell. 2002 Apr 5;109(1):113-24.
    PMID 11955451
     
    Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions.
    Li YL, Tian Z, Wu DY, Fu BY, Xin Y.
    World J Gastroenterol. 2005 Jan 14;11(2):285-8.
    PMID 15633233
     
    Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.
    Liu YC, Shen CY, Wu HS, Hsieh TY, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Chen PJ, Hsieh CB, Chen TW, Hsu HM.
    World J Gastroenterol. 2006 Apr 14;12(14):2168-73.
    PMID 16610016
     
    Gastric cancer.
    Lochhead P, El-Omar EM.
    Br Med Bull. 2008;85:87-100. Epub 2008 Feb 10.
    PMID 18267927
     
    Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
    Miettinen M, Lasota J.
    Arch Pathol Lab Med. 2006 Oct;130(10):1466-78.
    PMID 17090188
     
    Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
    Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP.
    Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7.
    PMID 11219776
     
    Prognostic value of numerical aberrations of chromosome 17 in differentiated gastric cancer: evaluation by multivariate regression analysis.
    Onchi H, Hirose K, Yamaguchi A, Noriki S, Fukuda M.
    Oncol Rep. 2000 Nov-Dec;7(6):1317-22.
    PMID 11032936
     
    Non-random structural chromosomal changes in primary gastric cancer.
    Panani AD, Roussos C.
    Cancer Lett. 2005 Jul 28;225(2):291-5. Epub 2005 Jan 13.
    PMID 15978333
     
    Cytogenetic and molecular aspects of gastric cancer: clinical implications.
    Panani AD.
    Cancer Lett. 2008 Aug 8;266(2):99-115. Epub 2008 Apr 1.
    PMID 18381231
     
    Gastric polyps: classification and management.
    Park do Y, Lauwers GY.
    Arch Pathol Lab Med. 2008 Apr;132(4):633-40.
    PMID 18384215
     
    Global cancer statistics, 2002.
    Parkin DM, Bray F, Ferlay J, Pisani P.
    CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.
    PMID 15761078
     
    Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype.
    Pinto M, Wu Y, Mensink RG, Cirnes L, Seruca R, Hofstra RM.
    Cancer Genet Cytogenet. 2008 Jan 15;180(2):110-4.
    PMID 18206535
     
    Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
    Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, Wang TH, Chuang SM.
    Hepatogastroenterology. 1997 Mar-Apr;44(14):604-9.
    PMID 9164544
     
    Higher frequencies of numerical aberrations of chromosome 17 in primary gastric cancers are associated with lymph node metastasis.
    Terada R, Yasutake T, Yamaguchi E, Hisamatsu T, Nakamura S, Ayabe H, Tagawa Y.
    J Gastroenterol. 1999 Feb;34(1):11-7.
    PMID 10204605
     
    Clinical implications of chromosomal abnormalities in gastric adenocarcinomas.
    Wu CW, Chen GD, Fann CS, Lee AF, Chi CW, Liu JM, Weier U, Chen JY.
    Genes Chromosomes Cancer. 2002 Nov;35(3):219-31.
    PMID 12353264
     
    Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma.
    Yamac D, Ayyildiz T, Cos,kun U, Akyurek N, Dursun A, Seckin S, Koybasioglu F.
    Pathol Res Pract. 2008;204(8):527-36. Epub 2008 May 6.
    PMID 18462890
     
    Recurrent chromosomal rearrangements at bands 8q24 and 11q13 in gastric cancer as detected by multicolor spectral karyotyping.
    Yamashita Y, Nishida K, Okuda T, Nomura K, Matsumoto Y, Mitsufuji S, Horiike S, Hata H, Sakakura C, Hagiwara A, Yamagishi H, Taniwaki M.
    World J Gastroenterol. 2005 Sep 7;11(33):5129-35.
    PMID 16127741
     
    Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.
    Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T.
    Cancer Res. 1991 Feb 1;51(3):1034-8.
    PMID 1670998
     

    Citation

    This paper should be referenced as such :
    Lochhead, P ; El-Omar, E
    Gastric Tumors: an overview
    Atlas Genet Cytogenet Oncol Haematol. 2009;13(10):761-767.
    Free journal version : [ pdf ]   [ DOI ]
    On line version : http://AtlasGeneticsOncology.org/Tumors/GastricTumOverviewID5410.html


    Other genes implicated (Data extracted from papers in the Atlas) [ 326 ]

    Genes ADAM10 ADAM17 ADAM23 ADAM9 ADAMTS9 AFAP1L2 AFP AGER AKAP12 AKT1
    AKT1S1 ALCAM AMFR ANG ANXA1 ARID1A ASCL1 ATG2B ATP2B4 ATR
    AXL B3GNT6 BAK1 BCAR1 CCND1 CCND1 BCL2L15 BCL6 BIRC6 BMP4
    BNIP3L BRCA2 BTRC BYSL CALR CAPG CASP7 CASP8 CAV1 CBX7
    CCNB1 CCR2 CD44 CD74 CD82 CDC20 CDC25A CDC25A CDC25A CDH17
    CDH1 CDH3 CEACAM1 CENPW CFLAR CHD5 CHD6 CHFR CKS2 CLIC1
    COL1A2 CRTC2 CTSL CXCL17 CXCL5 CYB5A CYP2A6 CYP2W1 CYP4B1 DAPK1
    DCC DDC DKK3 DLC1 DNMT1 DNMT3A DOCK1 DSG2 E2F4 ECM1
    EEF1A1 EGR1 EHMT2 EIF2AK2 EIF3A EIF4B EMP3 ENG ENOX2 EPHA2
    EPHA3 ERBB2 ERGIC3 ETV4 EZH2 FAM107B AMER1 FAS FBLN1 FEN1
    FGF1 FGF2 FGFR2 FGFR4 FHL2 FOXM1 FOXQ1 FRZB FUT8 FXYD3
    GAB2 GADD45A GALNT6 GAST GDF15 GPX1 GPX3 GSDMA GSDMB GSTA1
    GSTM1 HACE1 HDAC2 HGF HLA-G HLTF HNF4A HRK HSPB1 HSPB8
    HTATIP2 HTRA1 HTRA2 ICAM1 ID1 ID4 IDH2 IGFBP6 IL17A
    IL1B IL1RN IL23A ILK ING1 ING4 IRF1 IRS2 KCMF1 KCNH1
    KDR CEMIP KIAA1524 KLF4 KLK12 KLK13 LDOC1 LGALS3 LMO1 LOX
    LOXL2 LPAR2 LZTS1 MACROD1 MAGEA3 MAL MAPK1 MAPK3 MAPK4 MBD2
    MCC MCM3 MERTK RIOX2 MIR106B MIR107 MIR122 MIR126 MIR133B MIR135A1
    MIR141 MIR150 MIR191 MIR196B MIR200C MIR27A MIR296 MIR30A MIR331 MIR373
    MIR429 MIR449A MIR744 MKI67 MMP14 MMP2 MSH2 MSH3 MSH6 MSX2
    MTA3 MUC13 MUC2 MUC5AC MUC6 MYEOV MYO1A NAMPT NDRG2 NET1
    NME1 NNMT NR3C1 OLFM4 OPCML OSGIN1 EP300 TP53 PRKN
    PARK7 PDCD5 PDSS2 PDX1 PFKFB2 PFKFB3 PFKFB4 PGR PIAS1 PIK3CA
    PIM1 PIWIL1 PIWIL2 PLA2G2A PLCD1 PLCG1 PPP1R1B PPP1R9B PRDM2 PRKCI
    PRUNE1 PSCA PTMA PTPN13 PTPRA RAC3 RACGAP1 RAF1 RAN RASSF2
    RASSF6 RHOA RHOBTB1 RHOBTB2 RND3 ROR2 ROS1 RPRM RPS27 RRM2
    S100A10 S100A2 S100A4 S100A7 S100P SCD SDC1 SDCBP SFRP4 SH3GL2
    SHC1 SIAH1 SIRT1 SLC16A1 SLC19A3 SLC4A1 SLC5A8 SLPI SNAI1
    SNCG SOCS6 SOX2 SPARC SPINK1 SPINT1 SPP1 SRC SRSF3 SSX2
    ST6GALNAC1 STAG2 STARD13 STK11 STMN1 SULF1 SYK TACC1 TBX3 TEK
    TGFBR2 TIE1 TMPRSS4 TNFRSF11B TNKS TP53BP2 TP53INP1 TPBG TRIO TSPAN8
    TWIST1 TXN UBD UBE2C VAV3 VCP VDAC1 NSD2 WIF1 WNT1
    WNT5A WWC1 XRCC5 ZBTB33 ZBTB7A ZFX

    External links

    arrayMap Topo ( C16) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
     
     
    Other databaseICGC Data Portal - [GACA-CN] Gastric Cancer - CN
    Other databaseICGC Data Portal - [STAD-US] Gastric Adenocarcinoma - TCGA, US
    Other databaseGastric Cancer (My Cancer Genome)
    Other databaseGIST ( My Cancer Genome)
    Other databaseStomach adenocarcinoma (STAD) TCGA Copy Number Portal
    Other databaseStomach and Esophageal carcinoma (STES) TCGA Copy Number Portal
    Other databaseStomach adenocarcinoma ( intOGen )
    Other databaseStomach adenocarcinoma ( intOGen )
    Other databaseGastric Adenocarcinoma (TCGA)(OASIS Portal)
    Other databaseGastric Cancer (HKU)(OASIS Portal)
    Other databaseStomach Cancer Overview - Disease Synopsis [canSAR]
    Other databaseStomach Adenocarcinoma [ Genomic Data Commons - NCI TCGA-STAD]
    Disease databaseGastric Tumors: an overview
    REVIEW articlesautomatic search in PubMed
    Last year articlesautomatic search in PubMed


    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Mon Sep 18 17:21:17 CEST 2017


    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    jlhuret@AtlasGeneticsOncology.org.